YOLFTbeta
X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc

XFOR · NASDAQ · Healthcare / Biotechnology

3.12USD-0.05 (-1.58%)

Price History

Full chart

Market Stats

Previous Close3.17
Open3.20
Day Range2.98 – 3.20
52-Week Range2.80 – 4.83
Volume501.34K
Market Cap287.53M
P/E (TTM)2.03
Forward P/E0.00
EPS1.43
Dividend Yield0.00%
Beta0.40
50-Day Avg3.86
200-Day Avg3.92

About

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Adam R. Craig M.B.A., M.D., Ph.D.
  • Employees45
  • Headquarters61 North Beacon Street, Boston, MA, United States, 02134, USA
  • Websitehttps://www.x4pharma.com

Leadership

  • Dr. Adam R. Craig M.B.A., M.D., Ph.D.Executive Chair · b. 1966
  • Mr. John P. Volpone M.B.A.President & COO · b. 1975
  • Mr. David H. KirskeCFO, Treasurer & Corporate Secretary · b. 1954
  • Dr. Richard Peters M.D., Ph.D.Founder · b. 1962
  • Dr. Renato T. Skerlj Ph.D.Founder
  • Dr. Keith T. Flaherty M.D.Founder & Member of Corporate Advisory Board · b. 1971

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-003.50M3.00M3.00M0002.56M35.11M
Growth (%)-----14.29%0.00%-100.00%---+1273.21%
Cost of Revenue400.00K300.00K195.00K103.00K672.00K1.23M1.89M1.99M2.00M797.00K6.26M
Gross Profit-400.00K-300.00K-195.00K-103.00K-672.00K3.00M-1.89M-1.99M-2.00M1.76M28.86M
Gross Margin----2.94%-22.40%100.00%---68.83%82.18%
Operating Expense14.43M24.05M35.94M28.98M46.13M62.87M73.46M85.58M105.53M38.16M115.74M
Operating Income-14.82M-24.35M-36.13M-29.09M-46.80M-59.87M-75.35M-87.57M-107.52M-36.40M-86.88M
Operating Margin----831.00%-1560.10%-1995.80%----1423.58%-247.44%
EBITDA-14.43M-24.05M-35.94M-28.98M-46.13M-59.52M-83.14M-89.33M-94.89M-27.58M-69.00M
EBITDA Margin----828.06%-1537.70%-1984.10%----1078.45%-196.52%
Net Income-13.22M-22.98M-33.88M-33.28M-52.81M-62.13M-88.70M-93.87M-101.17M-37.45M-79.20M
Net Income Margin----951.00%-1760.23%-2071.03%----1464.61%-225.55%
R&D12.71M17.83M28.13M20.35M30.16M41.93M48.76M61.06M72.02M81.64M72.22M
R&D as % of Total Revenue---581.31%1005.43%1397.73%---3192.92%205.69%
Interest Expense472.00K2.52M2.08M720.00K2.15M2.69M3.64M3.99M5.78M8.77M8.88M
Interest Expense % of Total Revenue---20.57%71.57%89.60%---342.90%25.28%

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets9.51M7.60M81.25M36.00M160.70M122.87M117.18M155.59M147.26M146.45M290.46M
Total Liabilities13.88M24.33M22.55M14.40M31.48M50.07M52.76M81.53M96.16M124.30M104.17M
Total Equity-4.37M-16.72M58.71M21.60M129.22M72.80M64.41M74.05M51.10M22.15M186.29M
Cash6.76M3.04M76.79M30.75M126.18M78.97M81.79M121.72M99.22M55.70M217.05M
Total Debt7.19M15.26M12.24M9.58M22.91M38.45M39.78M38.42M58.28M78.09M77.28M
Net Debt434.00K12.23M-64.56M-22.86M-103.27M-40.52M-42.00M-83.30M-40.94M22.39M-139.76M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-10.82M-21.64M-27.87M-25.42M-48.05M-58.82M-70.91M-77.10M-96.51M-130.90M-85.62M
Investing Cash Flow-247.00K-138.00K-42.00K-34.00K27.23M-1.36M-615.00K-103.00K-14.88M66.99M8.15M
Financing Cash Flow11.51M18.15M101.26M6.87M140.66M12.39M74.25M117.23M88.52M20.29M238.63M
Capital Expenditure170.00K73.00K42.00K34.00K174.00K1.36M615.00K103.00K60.00K7.33M3.00M
Free Cash Flow-10.99M-21.71M-27.91M-25.42M-48.23M-60.18M-71.52M-77.20M-96.57M-138.23M-88.62M
Dividends Paid--45.68M-19.95M12.39M13.94M12---
FCF to OCF101.57%100.34%100.15%100.00%100.36%102.32%100.87%100.13%100.06%105.60%103.50%
Dividend Paid to FCF---163.66%--41.37%-20.58%-19.50%-0.00%---

Earnings

Report DateMay 4, 2017Sep 20, 2017Nov 17, 2017Mar 9, 2018May 10, 2018Aug 13, 2018Nov 9, 2018Mar 11, 2019May 15, 2019Aug 7, 2019Nov 7, 2019Mar 12, 2020May 7, 2020Jul 30, 2020Nov 5, 2020Mar 4, 2021May 6, 2021Aug 3, 2021Nov 4, 2021Mar 17, 2022May 12, 2022Aug 4, 2022Nov 3, 2022Mar 21, 2023May 4, 2023Aug 10, 2023Nov 9, 2023Mar 21, 2024May 7, 2024Aug 8, 2024Nov 13, 2024Mar 19, 2025May 1, 2025Aug 8, 2025Nov 5, 2025Mar 17, 2026May 6, 2026Aug 6, 2026Nov 4, 2026
EPS Estimate0.000.00--17.80-6.24-4.90-3.88-4.44-98.97-29.10-32.00-25.65-0.80-21.54-21.97-0.90-25.76-22.08-21.30-0.68-18.53-19.25-9.53-7.24-0.22-4.93-4.29-4.55-0.160.75-5.16-0.16-3.75-4.34-0.79-0.35-0.20-0.19-0.19
EPS Actual-0.50-0.53-24.36-10.08-4.44-5.10-4.56-3.92-200.10-30.60-36.60-19.80-0.56-22.80-26.10-0.91-39.00-22.20-22.80-0.90-21.60-18.00-7.80-8.70-0.16-9.90-0.30-3.00-0.26-2.12-5.40-0.200.04-3.47-0.69-0.22-0.16-0.13-
Surprise---43.37%28.85%-4.08%-17.53%11.71%-102.18%-5.15%-14.38%22.81%30.00%-5.85%-18.80%-1.11%-51.40%-0.54%-7.04%-32.35%-16.57%6.49%18.15%-20.17%27.27%-100.81%93.01%34.07%-62.50%-382.67%-4.65%-26.98%101.07%20.05%12.66%36.69%20.00%31.58%-
Timing--After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-market-Pre-marketAfter-hours-

Key Statistics & Ratios

Market Cap287.53M
Enterprise Value177.60M
Trailing P/E2.03
Forward P/E0.00
Price / Sales18.14
Price / Book1.98
EPS1.43
Book Value1.62
Revenue (TTM)15.85M
Gross Profit (TTM)12.92M
EBITDA-79.00M
Profit Margin0.00%
Operating Margin-186.13%
Return on Equity-113.08%
Return on Assets-28.15%
Shares Outstanding99.15M
Shares Float57.25M
Beta0.40
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 5 analystsTarget 11.60
  • Strong Buy
    3
  • Buy
    2

Ownership Breakdown

Institutions
103.81%
Insiders
0.44%
Retail / Other
0.00%

Top Institutional Holders

  • Morgan Stanley - Brokerage Accounts
    9.47M9.55%
  • FMR Inc
    8.10M8.17%
  • Bain Capital Life Sciences Investors, LLC
    7.97M8.04%
  • Perceptive Advisors LLC
    7.93M8.00%
  • Kalehua Capital Management LLC
    7.45M7.51%
  • Saturn V Capital Management LLC
    6.97M7.03%
  • Empery Asset Management, LP
    6.93M6.99%
  • Deep Track Capital, LP
    5.88M5.93%
  • Vanguard Capital Management, LLC
    3.50M3.53%
  • BRAIDWELL LP
    3.27M3.30%
  • Rosalind Advisors, Inc.
    3.21M3.24%
  • Blackstone Inc
    2.68M2.71%
  • Trails Edge Capital Partners, LP
    2.57M2.59%
  • Nantahala Capital Management, LLC
    2.45M2.47%
  • Bvf Inc
    2.23M2.25%

Top Fund Holders

  • Fidelity Small Cap Growth
    3.39M3.42%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.60M2.62%
  • Morgan Stanley Inst Inception I
    2.31M2.33%
  • iShares Russell 2000 ETF
    1.96M1.98%
  • EQ/Morgan Stanley Small Cap Growth K
    1.92M1.93%

Stock Splits

  • Apr 28, 20251:30
  • Mar 14, 20191:6